Fig. 6
From: Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
Real time qPCR analysis of IFNγ, TNFα, IL-12, IL-10, TIM3, CTLA-4, PD-L1 and Ido-1 expressed by mRNA from three dimensional spheroid cultures before (Control) and after treatment with MEK-inhibitor, selumetinib, anti-PD-L1 drug, atezolizumab, and Ido-1 inhibitor as single agents and in triple combination. Results were normalized to 18S mRNA and analyzed by ΔCt method. One-way ANOVA test followed by Tukey’s test were used for statistical analysis (**p < 0.01)